(1995; 152 pages) [French] [Spanish]
Group: anthelminthic agent
Chewable tablet 200 mg, 400 mg
A benzimidazole derivative that interferes with micro tubule assembly and blocks glucose uptake by many intestinal and tissue nematodes and some cestodes.
It is poorly absorbed from the gastrointestinal tract and is rapidly and extensively metabolized in the liver. The absorbed fraction, which has a plasma half-life of some 8 hours, is largely eliminated in the bile and urine as the sulfoxide.
Treatment of Echinococcus multilocularis infections, E. granulosus infections prior to or not amenable to surgery, and neurocysticercosis.
Dosage and administration
Adults: up to four 30-day courses of 10-15 mg/kg daily in two divided doses separated by treatment-free periods of 15 days. Patients with E. multilocularis infections may need further treatment cycles.
Adults: 15 mg/kg daily for 30 days. Early data suggest that an 8-day course may be as effective.
• Known hypersensitivity.
Liver function and blood counts should be monitored at least twice during each cycle of treatment and further treatment cycles should not be initiated unless values are within normal limits.
Use in pregnancy
Albendazole has been shown to have teratogenic and embryotoxic potential in rats and rabbits. It should not be administered during confirmed or suspected pregnancy.
Transient gastrointestinal discomfort and headache have occasionally been reported.
Reversible increases in serum levels of hepatic enzymes and reversible reductions in leukocyte counts occur.
Rash and fever have been reported rarely during the early stages of treatment. Alopecia has been reported in a small percentage of patients.
Emesis or gastric lavage may be of value if undertaken within a few hours of ingestion. Otherwise treatment is symptomatic and supportive. No specific antidote exists.
Tablets should be stored in well-closed containers.